Apellis Pharmaceuticals, Inc. which can be found using ticker (APLS) have now 15 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 156 and 76 calculating the mean target price we have $103.53. Given that the stocks previous close was at $87.48 and the analysts are correct then there would likely be a percentage uptick in value of 18.3%. There is a 50 day moving average of $78.87 and the 200 moving average now moves to $62.24. The company has a market cap of 10.03B. The current share price for the company is: 86.09 USD
The potential market cap would be $11,865,217,634 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 0.96 and a -37.69% return on assets.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. Its SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). The Company’s EMPAVELI (pegcetacoplan) is the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) is the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has an approval for the treatment of PNH in Saudi Arabia, Australia, and the United Kingdom. Systemic pegcetacoplan markets under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union and United Kingdom.
